11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer

European Urology

Volumn 44, Issue 1, 2003, Pages 32-39

  De Jong, I J ^a   Pruim, J ^a   Elsinga, P H ^a   Vaalburg, W ^a   Mensink, H J A ^a   Jakse, G ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

11C choline; PET; Prostate cancer; Treatment evaluation

Indexed keywords

CHOLINE C 11; HORMONE; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CHOLINE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MULTIMODALITY CANCER THERAPY; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME; TUMOR LOCALIZATION; AFTERCARE; BRACHYTHERAPY; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EVALUATION; METHODOLOGY; MIDDLE AGED; MONITORING; NEEDLE BIOPSY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

AFTERCARE; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BRACHYTHERAPY; CHOLINE; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0038311920     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00207-0     Document Type: Article

References (32)

1. W.R. Morgan E.J. Bergstrahl H. Zincke Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer Urology 41 1993 113 120
2. A. Stein J.B. deKernion F. Dorey Prostatic specific antigen related to clinical status 1–14 years after radical retropubic prostatectomy Br. J. Urol. 67 1991 626 631
3. T.A. Stamey M.K. Ferrari H. Schmid The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of the patients J. Urol. 150 1993 1856 1859
4. P.H. Lange C.J. Ercole D.J. Lightner E.E. Fraley R. Vessella The value of serum prostate specific antigens determinations before and after radical prostatectomy J. Urol. 141 1989 873 879
5. A.W. Partin J.D. Pearson P.K. Landis H.B. Carter C.R. Pound J.Q. Clemens Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases Urology 43 1994 649 659
6. L.S. Foster P. Jajodia G. Fournier K. Shinohara P. Carroll P. Narayan The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy J. Urol. 149 1993 1024 1028
7. D.A. Kapoor N.F. Wasserman G. Zhang P.K. Reddy Value of transrectal ultrasound in identifying local disease after radical prostatectomy Urology 41 1993 594 597
8. M.L. Schiebler M. Schnall H.M. Pollack R.E. Lenkinski J.E. Tomaszewski A.J. Wein Current role of MR imaging in the staging of adenocarcinoma of the prostate Radiology 189 1993 339 352
9. P.J. Effert R. Bares S. Handt J.M. Wolff U. Bull G. Jakse Metabolic imaging of untreated prostate cancer by positron emission tomography with 18F-fluorine-labeled deoxyglucose J Urol. 155 1996 994 998
10. C.K. Hoh M.A. Seltzer J. Franklin J.B. deKernion M.E. Phelps A. Belldegrun Positron emission tomography in urological oncology J. Urol. 159 1998 347 356
11. C. Hofer C. Laubenbacher J. Breul R. Hartung M. Schwaiger Flurine-18-fluordeoxyglucose positron emission tomography is useless for detection of local recurrence after radical prostatectomy Eur Urol. 36 1999 31 35
12. T. Hara N. Kosaka T. Kondo H. Kishi O. Kobori Imaging of brain tumor, lung cancer, esophagus cancer, colon cancer, prostate cancer, and bladder cancer with [C-11]-choline J. Nucl. Med. 38 1997 250P
13. S.H. Zeisel Dietary choline: biochemistry Ann. Rev. Nutr. 1 1981 95 121
14. F. Podo Tumor phospholipid metabolism NMR Biomed. 12 1999 413 439
15. T. Hara N. Kosaka H. Kishi PET imaging of prostate cancer using carbon-11-choline J. Nucl. Med. 39 1998 990 995
16. J. Kotzerke J. Prang B. Neumaier B. Volkmer A. Gulhmann K. Kleinschnmidt Experience with carbon-11-choline positron emission tomography in prostate carcinoma Eur. J. Nucl. Med. 27 2000 1415 1419
17. 11 C -choline positron emission tomography Eur. Urol. 42 2002 18 23
18. 11 C -choline PET J. Nucl. Med. 44 2003 331 335
19. 18 F ] Fluoroethyl-dimethyl-2-oxyethylammonium (choline analog): automated synthesis and tumor imaging J. Labelled Compounds Radiopharm 40 1997 670
20. H. Hricak G.C. Doms R.B. Jeffrey A. Avallone D. Jacobs W.K. Benton Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging Radiology 162 1987 331 336
21. R.H. Oyen H.P. Van Poppel F.E. Ameye W.A. Van de Voorde A.L. Baert L.V. Baert Lymph node staging of localized prostate carcinoma with CT and CT guided fine needle aspiration biopsy: prospective study of 285 patients Radiology 190 1991 315 322
22. G.J. Jager J.O. Barentsz G.O. Oosterhof J.A. Witjes S.J.H. Ruijs Pelvic adenopathy in prostate and bladder cancer: MRI imaging with a three dimensional T1 weighted magnetization prepared-rapid gradient echo and two dimensional Spin-echo sequences Am. J. Roentgenol. 167 1996 1503 1507
23. M.K. Haseman N.L. Reed S.A. Rosenthal Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate specific antigen. Positron emission tomography and biopsy correlation Clin. Nucl. Med. 21 1996 704 713
24. G. Sanz J.E. Robles M. Gimenez J. Arocena D. Sanchez F. Rodriguez-Rubio Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer BJU Int. 84 1999 1028 1031
25. M.J. Morris T. Akhurst I. Osman R. Nunez H. Macapinlac K. Siedlecki Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer Urology 59 2002 913 918
26. M.A. Seltzer S. Jahan M. Dahlbom D.B. Stout N. Satyamurthy M.E. Phelps 11C-acetate PET imaging of primary and locally recurrent prostate cancer: comparison to normal controls J. Nucl. Med. 43 Suppl 2002 117P [Abstract]
27. J. Kotzerke B.G. Volkmer B. Neumaier J.E. Gschwend R.E. Hautmann S.E. Reske Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer Eur. J. Nucl. Med. 29 2002 1380 1384
28. N. Oyama H. Akino H. Kanamaru Y. Suzuki S. Muramoto Y. Yonekura 11C-acetate PET imaging of prostate cancer J. Nucl. Med. 43 2002 181 186
29. J. Kotzerke J.E. Gschwend B. Neumaier PET for prostate cancer imaging: still a quandary or the ultimate solution? J. Nucl. Med. 43 2002 200 2002
30. 18 F -labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer Cancer Res. 61 2001 110 117
31. A. Dimitrakopoulou-Strauss L.G. Strauss PET imaging of prostate cancer with 11C-acetate J. Nucl. Med. 44 2003 556 558
32. N. Oyama T.R. Miller F. Dehdashti B.A. Siegel K.C. Fischer J.M. Michalski 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse J. Nucl. Med. 44 2003 549 555